Visualization Analysis of Research Hotspots and Trends in Field of Tumor Therapy Based on CiteSpace and VOSviewer
-
摘要:目的
探索近10年恶性肿瘤治疗领域的研究热点及发展趋势。
方法分别在中国知网、Web of Science核心合集数据库，检索近10年中英文肿瘤治疗领域相关文献，选取文献计量学的研究方法，对发表文献关键词聚类分析。
结果共检索到中文文献45 455篇，英文文献866 958篇。结合可视化分析结果及当前肿瘤治疗的研究困境，目前国内外肿瘤治疗研究热点主要集中在四个领域：靶向治疗领域，包括药物靶点新发现、克服靶向治疗耐药、单克隆抗体及抗体-药物偶联物的开发；免疫治疗领域，重点是提高免疫检查点抑制剂应答率，解决免疫治疗耐药机制，改善治疗安全性；中医药研究领域，包括中医药治疗循证评价研究、中医药优势人群筛选及改善生活质量；新药研发领域，主要涉及类器官抗癌药物筛选、合成生物学及人工智能等前沿技术研究。
结论新型靶向药物研究、免疫疗效提升、多学科交叉融合、纳米递送、中医药创新研究等是肿瘤治疗领域研究的重点方向。
Abstract:ObjectiveTo explore the research hotspots and development trends in the field of cancer treatment in the past decade.
MethodsThe CNKI and Web of Science Core Collection databases were searched for Chinese and English articles related to cancer treatment published over the last 10 years. Bibliometric research methods were employed, including keyword cluster analysis of published literature.
ResultsA total of 45 455 Chinese articles and 866 958 English articles were retrieved. Combining the visualization analysis results and the current research dilemma of tumor treatment revealed that the current research hotspots of tumor treatment domestically and internationally can primarily focus on four key areas. In the realm of targeted therapy, efforts are directed towards the discovery of new drug targets, overcoming resistance to targeted therapy, and the development of monoclonal antibodies and antibody–drug conjugates. In the field of immunotherapy, the emphasis lies in enhancing the response rate to immune checkpoint inhibitors, determining the mechanisms behind resistance to immunotherapy, and improving the safety of treatment. The research in traditional Chinese medicine (TCM) covers evidence-based evaluation studies on TCM treatment, the identification of populations that can gain the most benefit from TCM, and strategies for improving the quality of life. In the area of novel drug development, cutting-edge technologies, such as organoid-based screening for anticancer drugs, synthetic biology, and artificial intelligence, are under investigation.
ConclusionNew targeted drugs, immune efficacy improvement, multidisciplinary integration, nano-delivery, and TCM innovation are the key research directions in the field of tumor therapy in the future.
-
Competing interests: The authors declare that they have no competing interests.利益冲突声明：所有作者均声明不存在利益冲突。作者贡献：方宇航、张楚楚：研究选题与设计、论文撰写与修改隋白鹭、王妍、王润兮：图片绘制及表格制作陈宇、袁欣禾：数据收集及统计分析杨洪军、张英：研究选题与设计、论文指导与修改
-
![]()
图 1 肿瘤治疗领域中英文关键词共现图谱
Figure 1 Co-occurrence map of Chinese and English keywords in the field of cancer therapy
![]()
图 2 肿瘤靶向治疗领域中英文关键词共现图谱
Figure 2 Co-occurrence map of Chinese and English keywords in the field of tumor targeted therapy
![]()
图 3 肿瘤免疫治疗领域中英文关键词共现图谱
Figure 3 Co-occurrence map of Chinese and English keywords in the field of tumor immunotherapy
![]()
图 4 肿瘤中医药治疗领域中英文关键词共现图谱
Figure 4 Co-occurrence map of Chinese and English keywords in the field of tumor treatment with traditional Chinese medicine
![]()
图 5 肿瘤新药研发领域中英文关键词共现图谱
Figure 5 Co-occurrence map of Chinese and English keywords in the field of research and development of novel anti-cancer agent
表 1 肿瘤治疗领域中英文关键词频率表(前10位)
Table 1 Frequency table of Chinese and English keywords in the field of cancer therapy (Top 10)
Ranking Frequency Chinese
keywordsFrequency English
keywords1 114 乳腺癌 3255 Cancer 2 112 免疫治疗 1723 Therapy 3 106 肿瘤 1669 Immunotherapy 4 86 肺癌 1663 Expression 5 84 治疗 1378 Nanoparticles 6 83 指南 1042 Open label 7 75 诊断 1010 Breast cancer 8 64 胃癌 973 Survival 9 62 专家共识 969 Cells 10 59 综述 944 In vitro 
下载: 导出CSV
表 2 肿瘤靶向治疗领域中英文关键词频率表(前10位)
Table 2 Frequency table of Chinese and English keywords in the field of tumor targeted therapy (Top 10)
Ranking Frequency Chinese
keywordsFrequency English
keywords1 1094 靶向治疗 16036 Cancer 2 271 免疫治疗 12314 Expression 3 213 肿瘤 10873 Therapy 4 96 乳腺癌 7601 Immunotherapy 5 88 肺肿瘤 5910 Cells 6 59 综述 5244 Nanoparticles 7 59 肿瘤治疗 4915 Apoptosis 8 58 肺癌 4914 Targeted therapy 9 51 乳腺肿瘤 4900 Resistance 10 50 胃癌 4806 Survival
下载: 导出CSV
表 3 肿瘤免疫治疗领域中英文关键词频率表(前10位)
Table 3 Frequency table of Chinese and English keywords in the field of tumor immunotherapy (Top 10)
Ranking Frequency Chinese
keywordsFrequency English
keywords1 604 免疫治疗 37476 Immunotherapy 2 179 肿瘤 15551 Cancer 3 75 免疫疗法 12500 Expression 4 52 综述 7785 Therapy 5 49 肺肿瘤 6474 Survival 6 46 肿瘤疫苗 6243 T-cells 7 35 肺癌 6077 Tumor
microenvironment8 35 联合治疗 5605 Open label 9 30 免疫逃逸 5442 Nivolumab 10 29 靶向治疗 5224 Dendritic cells
下载: 导出CSV
表 4 肿瘤中医药治疗领域中英文关键词频率表(前10位)
Table 4 Frequency table of Chinese and English keywords in the field of tumor treatment with traditional Chinese medicine (Top 10)
Ranking Frequency Chinese
keywordsFrequency English
keywords1 336 中药 2318 Apoptosis 2 297 中医药 1844 Cancer 3 291 肿瘤 1651 Traditional
Chinese Medicine4 262 肺癌 1429 Expression 5 195 胃癌 1143 In vitro 6 181 乳腺癌 1000 Inflammation 7 178 恶性肿瘤 996 Cells 8 123 抗肿瘤 945 Activation 9 120 作用机制 795 Inhibition 10 108 肝癌 742 Proliferation
下载: 导出CSV
表 5 肿瘤新药研发领域中英文关键词频率表(前10位)
Table 5 Frequency table of Chinese and English keywords in the field of research and development of novel anti-cancer agent (Top 10)
Ranking Frequency Chinese
keywordsFrequency English
keywords1 36 肿瘤 14418 Cancer 2 29 新药研发 7562 Expression 3 20 临床试验 6703 Apoptosis 4 17 临床研究 6115 In vitro 5 14 作用机制 4551 Cells 6 13 药物研发 4455 Discovery 7 12 靶向治疗 4363 Therapy 8 11 抗肿瘤 4351 Nanoparticles 9 10 抗肿瘤药 3978 Drug discovery 10 10 新药 3699 Breast cancer
下载: 导出CSV
-
[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc.2024.01.006
[2] Steeg PS. Targeting metastasis[J]. Nat Rev Cancer, 2016, 16(4): 201-218. doi: 10.1038/nrc.2016.25
[3] 高峰, 刘徳军, 张宪伟, 等. 老年广泛期小细胞肺癌EP/EC方案化疗的疗效与安全性分析[J]. 实用医学杂志, 2020, 36(18): 2555-2558. [Gao F, Liu DJ, Zhang XW, et al. Efficacy and safety evaluation of EP/EC chemotherapy in elderly patients with extensive-stage small-cell lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2020, 36(18): 2555-2558.] doi: 10.3969/j.issn.1006-5725.2020.18.020 Gao F, Liu DJ, Zhang XW, et al. Efficacy and safety evaluation of EP/EC chemotherapy in elderly patients with extensive-stage small-cell lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2020, 36(18): 2555-2558. doi: 10.3969/j.issn.1006-5725.2020.18.020
[4] 刘丽桃, 谢妮, 郭文鹏. 纳米技术在乳腺癌化疗中的应用研究进展[J]. 癌变·畸变·突变, 2015, 27(1): 75-81. [Liu LT, Xie N, Guo WP. Research progress of nanotechnology in breast cancer chemotherapy[J]. Ai Bian·Ji Bian·Tu Bian, 2015, 27(1): 75-81.] Liu LT, Xie N, Guo WP. Research progress of nanotechnology in breast cancer chemotherapy[J]. Ai Bian·Ji Bian·Tu Bian, 2015, 27(1): 75-81.
[5] Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review[J]. Lancet Oncol, 2019, 20(11): e619-e626. doi: 10.1016/S1470-2045(19)30491-7
[6] Gowd V, Ahmad A, Tarique M, et al. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine[J]. Semin Cancer Biol, 2022, 86 (Pt 2): 624-644.
[7] Li G, Liu Y, Hu H, et al. Evolution of innovative drug R&D in China[J]. Nat Rev Drug Discov, 2022, 21(8): 553-554 doi: 10.1038/d41573-022-00058-6
[8] Clara JA, Monge C, Yang Y, et al. Targeting signalling pathways and the immune microenvironment of cancer stem cells-a clinical update[J]. Nat Rev Clin Oncol, 2020, 17(4): 204-232. doi: 10.1038/s41571-019-0293-2
[9] 刘慧, 李丽, 刘洋汉, 等. 肿瘤相关巨噬细胞靶向治疗研究进展[J]. 广西师范大学学报(自然科学版), 2022, 40(5): 286-299. [Liu H, Li L, Liu YH, et al. Advances in Targeted Therapy of Tumor-Associated Macrophages[J]. Guangxi Shi Fan Da Xue Xue Bao (Zi Ran Ke Xue Ban), 2022, 40(5): 286-299.] Liu H, Li L, Liu YH, et al. Advances in Targeted Therapy of Tumor-Associated Macrophages[J]. Guangxi Shi Fan Da Xue Xue Bao (Zi Ran Ke Xue Ban), 2022, 40(5): 286-299.
[10] 张宏, 卜嘉文. 结直肠癌靶向治疗的耐药机制及潜在解决方案[J]. 中国实用外科杂志, 2024, 44(7): 774-780. [Zhang H, Bu JW. Drug resistance mechanisms of targeted therapy of colorectal cancer and potential solutions[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2024, 44(7): 774-780.] Zhang H, Bu JW. Drug resistance mechanisms of targeted therapy of colorectal cancer and potential solutions[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2024, 44(7): 774-780.
[11] Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions[J]. Nat Rev Drug Discov, 2023, 22(2): 101-126. doi: 10.1038/s41573-022-00579-0
[12] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. doi: 10.1016/S0140-6736(10)61121-X
[13] 李静, 伍玉琳, 马翠翠, 等. 抗体偶联药物的研究进展[J]. 华西药学杂志, 2023, 38(5): 586-592. [Li J, Wu YL, Ma CC, et al. Research progress on antibody-drug conjugates[J]. Hua Xi Yao Xue Za Zhi, 2023, 38(5): 586-592.] Li J, Wu YL, Ma CC, et al. Research progress on antibody-drug conjugates[J]. Hua Xi Yao Xue Za Zhi, 2023, 38(5): 586-592.
[14] Fu Z, Li S, Han S, et al. Antibody drug conjugate: the "biological missile" for targeted cancer therapy[J]. Signal Transduct Target Ther, 2022, 7(1): 93. doi: 10.1038/s41392-022-00947-7
[15] Memon D, Schoenfeld AJ, Ye D, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer[J]. Cancer Cell, 2024, 42(2): 209-224. e9.
[16] Liu J, Fu M, Wang M, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress[J]. J Hematol Oncol, 2022, 15(1): 28. doi: 10.1186/s13045-022-01247-x
[17] 何香川, 刘明斌, 张晓燕, 等. 靶向肿瘤微环境(TME)免疫治疗策略的研究进展[J]. 复旦学报(医学版), 2020, 47(1): 128-134. [He XC, Liu MB, Zhang XY, et al. The immunotherapeutic strategy for tumor microenvironment (TME)[J]. Fudan Xue Bao (Yi Xue Ban), 2020, 47(1): 128-134.] He XC, Liu MB, Zhang XY, et al. The immunotherapeutic strategy for tumor microenvironment (TME)[J]. Fudan Xue Bao (Yi Xue Ban), 2020, 47(1): 128-134.
[18] 全家乐, 康彦良, 张万里, 等. 肿瘤免疫治疗中过继性细胞疗法的研究进展[J]. 药学进展, 2021, 45(10): 725-734. [Quan JL, Kang YL, Zhang WL, et al. Advances in Research on Adoptive Cell Therapy in Tumor Immunotherapy[J]. Yao Xue Jin Zhan, 2021, 45(10): 725-734.] Quan JL, Kang YL, Zhang WL, et al. Advances in Research on Adoptive Cell Therapy in Tumor Immunotherapy[J]. Yao Xue Jin Zhan, 2021, 45(10): 725-734.
[19] Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial[J]. Gut, 2018, 67(11): 2006-2016. doi: 10.1136/gutjnl-2018-315983
[20] Chen L, Zhu HM, Li Y, et al. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)[J]. Proc Natl Acad Sci U S A, 2021, 118(6): e2020382118. doi: 10.1073/pnas.2020382118
[21] Wang HY, Gong S, Li GH, et al. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)[J]. Blood Cancer J, 2022, 12(11): 158. doi: 10.1038/s41408-022-00753-y
[22] Cheng X, Huo J, Wang D, et al. Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients[J]. Front Pharmacol, 2017, 8: 344. doi: 10.3389/fphar.2017.00344
[23] Li Y, Gu J, Zhou H, et al. Traditional Chinese Medicine symptom patterns in patients with colorectal carcinoma[J]. J Tradit Chin Med, 2018, 38(2): 299-308. doi: 10.1016/j.jtcm.2018.03.004
[24] 苏春雨, 朱广辉, 李杰. 非小细胞肺癌术后患者症状分布规律及升陷汤加减的干预效果[J]. 中医杂志, 2020, 61(7): 601-606. [Su CY, Zhu GH, Li J. Symptoms Distribution Rules of Postoperative Non-small Cell Lung Cancer Patients and Intervention Effect of Modified Shengxian Decoction[J]. Zhong Yi Za Zhi, 2020, 61(7): 601-606.] Su CY, Zhu GH, Li J. Symptoms Distribution Rules of Postoperative Non-small Cell Lung Cancer Patients and Intervention Effect of Modified Shengxian Decoction[J]. Zhong Yi Za Zhi, 2020, 61(7): 601-606.
[25] 姚嘉麟, 赵艺, 焦丽静, 等. 益气养阴病证结合辨治肺癌表皮生长因子受体酪氨酸激酶抑制剂靶向治疗相关症状群的随机对照双盲临床研究[J]. 中华中医药杂志, 2023, 38(5): 2470-2476. [Yao JL, Zhao Y, Jiao LJ, et al. Effects of the herbal formula based on disease-syndrome combination of benefiting qi and nourishing yin treatment on symptom clusters associated with EGFR-TKI targeted therapy for lung cancer patients: A randomized, double-blind study[J]. Zhong Hua Zhong Yi Yao Za Zhi, 2023, 38(5): 2470-2476.] Yao JL, Zhao Y, Jiao LJ, et al. Effects of the herbal formula based on disease-syndrome combination of benefiting qi and nourishing yin treatment on symptom clusters associated with EGFR-TKI targeted therapy for lung cancer patients: A randomized, double-blind study[J]. Zhong Hua Zhong Yi Yao Za Zhi, 2023, 38(5): 2470-2476.
[26] Li H, Ma C, Chang S, et al. Traditional Chinese Medicine Decoctions Improve Longevity Following Diagnosis with Stage Ⅳ Esophageal Squamous Cell Carcinoma: A Retrospective Analysis[J]. Int J Gen Med, 2022, 15: 1665-1675. doi: 10.2147/IJGM.S346536
[27] 张百红, 岳红云. 合成生物学和肿瘤治疗[J]. 现代肿瘤医学, 2023, 31(13): 2533-2536. [Zhang BH, Yue HY. Synthetic biology and cancer therapy[J]. Xian Dai Zhong Liu Yi Xue, 2023, 31(13): 2533-2536.] doi: 10.3969/j.issn.1672-4992.2023.13.031 Zhang BH, Yue HY. Synthetic biology and cancer therapy[J]. Xian Dai Zhong Liu Yi Xue, 2023, 31(13): 2533-2536. doi: 10.3969/j.issn.1672-4992.2023.13.031
[28] Fang Z, Li P, Du F, et al. The role of organoids in cancer research[J]. Exp Hematol Oncol, 2023, 12(1): 69. doi: 10.1186/s40164-023-00433-y
[29] 管庆霞, 罗煜婷, 刘宇萌, 等. 人工智能在抗肿瘤药物研发中的应用与进展[J]. 中国现代应用药学, 2023, 40(23): 3318-3323. [Guan QX, Luo YT, Liu YM, et al. Application and Progress of Artificial Intelligence in Development of Anti-tumor Drugs[J]. Zhongguo Xian Dai Ying Yong Yao Xue, 2023, 40(23): 3318-3323.] Guan QX, Luo YT, Liu YM, et al. Application and Progress of Artificial Intelligence in Development of Anti-tumor Drugs[J]. Zhongguo Xian Dai Ying Yong Yao Xue, 2023, 40(23): 3318-3323.
[30] Al RA, Chakma R, Dewan K, et al. Current advanced drug delivery systems: Challenges and potentialities[J]. J Drug Deliv Sci Technol, 2022, 76: 103727. doi: 10.1016/j.jddst.2022.103727
[31] Henn JG, Aguirre TAS, Nugent M, et al. Cancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome[J]. J Drug Deliv Sci Technol, 2024, 91: 105254. doi: 10.1016/j.jddst.2023.105254
计量
- 文章访问数: 873
- HTML全文浏览量: 2173
- PDF下载量: 170
